RxDoctor Payments Data

Khalil Raffoul, MD

Ophthalmology · Toledo, OHNPI 1407851736

Payments from drug & device makers

$2,253in general payments, 2019–2025

Across 53 payments — averaging $42.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$487
  • Alcon$190
  • Johnson & Johnson$165
  • Boston Scientific$150
  • Medtronic$137
  • Pfizer$133
  • plus $992 from 13 others

What the payments were for

  • Food & beverage$2,253100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,253 in reported general payments places this provider in the 60th percentile of 640 ophthalmology providers in Ohio.

See all ophthalmology providers in Ohio

Medicare billing

Part B allowed, 2024
$175,835
Medicare patients
588
Services billed
1,642

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine17$22,851
LumiganBimatoprost18$10,102
CombiganBrimonidine Tartrate/Timolol22$9,902
Brimonidine Tartrate92$8,980
Prednisolone Acetate236$6,633
Latanoprost387$4,696
Timolol Maleate78$3,243
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol19$1,551
Loteprednol Etabonate12$1,441
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat122$1,279
Tobramycin163$704
Ketorolac Tromethamine50$541
Acyclovir27$334
Dorzolamide Hcl17$300
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha27$261

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$487$42,85557 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$98$1,44112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 640 ophthalmology providers in Ohio.

Other ophthalmology in Toledo

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →